Nektar Therapeutics (NKTR) Raw Materials (2010 - 2024)

Nektar Therapeutics' Raw Materials history runs 13 years deep, the most recent figure standing at $1.7 million for Q2 2024.

• On a quarterly basis, Raw Materials changed N/A year-over-year to $1.7 million in Q2 2024; TTM through Jun 2024 was $1.7 million, a N/A change from a year earlier, with the FY2023 full-year figure at $1.9 million, down 27.73% from the prior year.
• Raw Materials slipped to $1.7 million in Q2 2024 per NKTR's latest filing, from $1.9 million in the prior quarter.
• Across five years, Raw Materials topped out at $2.6 million in Q4 2022 and bottomed at $1.7 million in Q2 2024.
• The 3-year median for Raw Materials is $1.9 million (2023), against an average of $2.0 million.
• Biggest YoY gain for Raw Materials was 27.73% in 2023; the steepest drop was 27.73% in 2023.
• Year by year, Raw Materials stood at $2.6 million in 2022, then slipped by 27.73% to $1.9 million in 2023, then fell by 7.63% to $1.7 million in 2024.
• Per Business Quant, the three latest NKTR Raw Materials figures stand at $1.7 million (Q2 2024), $1.9 million (Q1 2024), and $1.9 million (Q4 2023).